Ziphius Vaccines is a global biopharmaceutical company dedicated to developing next-generation vaccines for the prevention of infectious diseases with major unmet global health needs.
The Company has developed a proprietary sa-RNA platform and is committed to leverage its' break-through technology by initiating multiple preclinical developments, consequently realizing further development to increase therapeutic potential.
Today, Ziphius Vaccines advances a portfolio of several mRNA-based vaccine candidates, with a focus on airborne, mucosal borne, and vector borne diseases.